Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$AMRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.18 up 157.14% YoY • Reported revenue of $796.2M up 9.89% YoY • Amneal Pharmaceuticals raised its full-year 2026 guidance, now expecting net revenue of $3.10 billion - $3.20 billion, adjusted EBITDA of $750 million - $780 million, and adjusted diluted EPS of $0.96 - $1.06.
3

Price since post

Full Details

Advertisement|Remove ads.